Gary Nachman
Stock Analyst at Raymond James
(2.61)
# 1,327
Out of 4,412 analysts
74
Total ratings
54.24%
Success rate
-0.52%
Average return
Main Sectors:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Reinstates: Market Perform | n/a | $269.98 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $14.53 | +106.47% | 4 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $4.07 | +71.99% | 1 | Mar 28, 2024 | |
| VERU Veru Inc. | Initiates: Outperform | $3 | $1.27 | +136.22% | 1 | Mar 28, 2024 | |
| ABBV AbbVie | Maintains: Outperform | $181 → $189 | $159.62 | +18.41% | 12 | Feb 6, 2024 | |
| PCRX Pacira BioSciences | Initiates: Outperform | $42 | $26.33 | +59.51% | 9 | Dec 20, 2023 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Outperform | $208 | $143.31 | +45.14% | 5 | Sep 29, 2023 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Market Perform | n/a | $109.46 | - | 7 | Sep 29, 2023 | |
| SDGR Schrödinger | Maintains: Outperform | $78 → $67 | $23.97 | +179.52% | 3 | Aug 3, 2023 | |
| AMRX Amneal Pharmaceuticals | Maintains: Market Perform | $5 → $4 | $5.87 | -31.86% | 2 | Mar 3, 2023 | |
| PHAT Phathom Pharmaceuticals | Maintains: Outperform | $35 → $30 | $9.18 | +226.80% | 4 | Mar 1, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $70 → $67 | $41.59 | +61.10% | 2 | Feb 23, 2023 | |
| ABCL AbCellera Biologics | Maintains: Outperform | $40 → $32 | $3.76 | +751.06% | 1 | Feb 22, 2023 | |
| VTRS Viatris | Downgrades: Market Perform | $16 → $14 | $11.57 | +21.00% | 2 | Feb 17, 2023 | |
| OPTN OptiNose | Maintains: Outperform | $6 → $5 | $0.86 | +481.13% | 3 | Nov 14, 2022 | |
| SAGE Sage Therapeutics | Maintains: Market Perform | $43 → $40 | $13.69 | +192.18% | 6 | Nov 9, 2022 | |
| TEVA Teva Pharmaceutical | Maintains: Market Perform | $11 → $10 | $13.81 | -27.59% | 1 | Nov 7, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Outperform | $4 → $3 | $1.10 | +172.73% | 2 | Nov 4, 2022 | |
| PYPD PolyPid | Maintains: Outperform | $810 → $750 | $4.75 | +15,679.51% | 2 | Aug 11, 2022 | |
| BHC Bausch Health Companies | Maintains: Market Perform | $15 → $8 | $8.71 | -8.15% | 2 | Aug 10, 2022 | |
| SCPH scPharmaceuticals | Maintains: Outperform | n/a | $4.49 | - | 2 | Jun 14, 2018 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Market Perform | n/a | $41.11 | - | 2 | Mar 13, 2018 |
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $269.98
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $14.53
Upside: +106.47%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.07
Upside: +71.99%
Veru Inc.
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $1.27
Upside: +136.22%
AbbVie
Feb 6, 2024
Maintains: Outperform
Price Target: $181 → $189
Current: $159.62
Upside: +18.41%
Pacira BioSciences
Dec 20, 2023
Initiates: Outperform
Price Target: $42
Current: $26.33
Upside: +59.51%
Alnylam Pharmaceuticals
Sep 29, 2023
Initiates: Outperform
Price Target: $208
Current: $143.31
Upside: +45.14%
Jazz Pharmaceuticals
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $109.46
Upside: -
Schrödinger
Aug 3, 2023
Maintains: Outperform
Price Target: $78 → $67
Current: $23.97
Upside: +179.52%
Amneal Pharmaceuticals
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $5.87
Upside: -31.86%
Phathom Pharmaceuticals
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $9.18
Upside: +226.80%
Ionis Pharmaceuticals
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $41.59
Upside: +61.10%
AbCellera Biologics
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.76
Upside: +751.06%
Viatris
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $11.57
Upside: +21.00%
OptiNose
Nov 14, 2022
Maintains: Outperform
Price Target: $6 → $5
Current: $0.86
Upside: +481.13%
Sage Therapeutics
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $13.69
Upside: +192.18%
Teva Pharmaceutical
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $13.81
Upside: -27.59%
Rigel Pharmaceuticals
Nov 4, 2022
Maintains: Outperform
Price Target: $4 → $3
Current: $1.10
Upside: +172.73%
PolyPid
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.75
Upside: +15,679.51%
Bausch Health Companies
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $8.71
Upside: -8.15%
scPharmaceuticals
Jun 14, 2018
Maintains: Outperform
Price Target: n/a
Current: $4.49
Upside: -
Amphastar Pharmaceuticals
Mar 13, 2018
Maintains: Market Perform
Price Target: n/a
Current: $41.11
Upside: -